Efficacy and safety of atezolizumab combined with bevacizumab-based chemotherapy in advanced malignancies: a systematic review and meta-analysis of randomized trials.

BMC Cancer · 2026 · PMC12973729 · PMID 41765886

Europe PMC DOI

hedged sentences

0.3240

closest p · 6.5× alpha

0.3240

boldest claim

The sentences

did not reach statistical significanceP = 0.324not close (p > 0.1)

Although the DCR was numerically greater in the intervention arm, this difference did not reach statistical significance (RR = 1.02; 95%CI: 0.98–1.07; P = 0.324).

also in 111,027 other papers

failed to reach statistical significanceno p-value reported

By contrast, the IMagyn050 study in advanced ovarian cancer failed to reach statistical significance for PFS improvement (19.5 vs. 18.4 months; HR = 0.92), despite a modest trend favoring the immunotherapy arm [ 34 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.